Boston Scientific Q3 2026 Earnings: Sales Up 1.5%, Margins Contract

Boston Scientific (NYSE: BSX) reported Q3 2026 net sales of $5.138 billion, up 1.5% year over year, while GAAP diluted EPS fell to $0.40 from $0.51. Gross and operating margins contracted as product costs increased faster than sales and the company recorded restructuring, litigation and impairment charges. Cardiovascular and Neuromodulation delivered growth, but Urology, Endoscopy and APAC declined.

Core Earnings Data

Reported, operational and organic sales each grew 1.5%, indicating that currency movements and recent acquisitions or divestitures had no material effect on consolidated growth for the quarter. The earnings picture was weaker: gross profit declined about 3.2%, and GAAP operating margin fell to approximately 16.1% from 20.7%.

Adjusted results showed less deterioration than GAAP figures but still declined. Adjusted net income attributable to common stockholders fell about 5.4%, while adjusted EPS decreased about 2.7%; a lower diluted weighted-average share count partially cushioned the per-share decline.

Business and Segment Performance

Cardiovascular generated most of the company’s absolute sales increase, rising $63 million to $3.406 billion. MedSurg grew only 0.6% on a reported basis as Neuromodulation’s double-digit expansion offset declines in Urology and Endoscopy.

Regional results were also mixed. LACA recorded the highest growth rate from a relatively small revenue base, while APAC was the only region to decline. EMEA’s 6.1% operational growth exceeded its reported growth, reflecting a negative currency effect on reported results.

The company also advanced its product pipeline by beginning enrollment in the Elite AF trial for its next-generation WATCHMAN Elite device. It received FDA 510(k) clearances for technologies within the StoneSmart ecosystem and for additional sizes of the SEISMIQ peripheral catheter, while entering a collaboration with Heartflow focused on AI-powered planning for coronary procedures. The release did not quantify any current-quarter revenue contribution from these developments.

Product Costs and Charges Turned Sales Growth Into Lower Earnings

Cost of products sold increased about 12.3% to $1.710 billion even though revenue rose only 1.5%. That difference reduced gross profit by $114 million and compressed gross margin by approximately 3.2 percentage points.

Operating expenses increased to $2.600 billion from $2.494 billion. SG&A declined by $58 million, but that reduction was outweighed by items including $81 million of litigation-related charges, $63 million of restructuring charges compared with an $8 million credit a year earlier, and $39 million of intangible asset impairment charges. As a result, GAAP operating income fell by $220 million and operating margin contracted by approximately 4.6 percentage points.

The smaller decline in adjusted results shows how these specified charges widened the gap between GAAP and non-GAAP performance. Even so, adjusted operating income decreased to $1.364 billion from $1.419 billion, and adjusted operating margin fell to approximately 26.5% from 28.0%, so the pressure was not limited to GAAP adjustments.

Guidance

Boston Scientific now expects full-year sales to grow, but its Q4 outlook calls for a year-over-year decline of 1.0% to 3.0% on both reported and organic bases. That represents a weaker year-over-year sales trajectory than the 1.5% growth recorded in Q3. The release did not provide previous guidance ranges, so the direction of any revision cannot be determined from the supplied information.

The company did not reconcile forward adjusted EPS guidance to GAAP EPS because it could not reasonably estimate items such as acquisition-related, restructuring, litigation and intangible asset impairment charges.

Management Commentary

Chairman and CEO Mike Mahoney described 2026 as a challenging year and highlighted the company’s response to the August cybersecurity incident, including work to restore operations and continue serving customers. Management did not quantify the incident’s specific effect on Q3 sales, margins or earnings in the release, making the pace of operational normalization an important factor to monitor alongside the Q4 sales outlook.

Risks Investors Need to Watch

• Expected Q4 sales contraction: Guidance for a 1.0% to 3.0% year-over-year decline indicates that near-term revenue pressure could intensify rather than ease.
• Margin pressure: Product costs rose substantially faster than sales in Q3, while adjusted operating margin also contracted. Continued cost pressure could limit earnings even if revenue stabilizes.
• Cybersecurity-related disruption: Management identified the August incident as a major challenge, but its financial impact was not quantified. Recovery progress remains relevant to operations and near-term results.
• Uneven business and regional performance: Urology, Endoscopy and APAC declined, leaving growth more dependent on Cardiovascular, Neuromodulation and faster-growing regions such as LACA.
• Charges affecting GAAP profitability: Restructuring, litigation and impairment expenses materially widened the gap between GAAP and adjusted earnings, and the company said similar items could materially affect future GAAP results.

Summary

Boston Scientific produced modest Q3 sales growth, led by Cardiovascular and Neuromodulation, but higher product costs and several operating charges caused a much sharper decline in GAAP earnings. Adjusted results were more stable but still showed lower profit and margin. The central issues for coming quarters are the expected Q4 sales contraction, recovery from the cybersecurity incident and whether the company can stabilize product costs and adjusted profitability.